Table 1 Paired tests between follow-up and baseline samples in PD and HCs (significant test results are printed in bold).
Paried tests (follow-up–baseline) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PD | Control | PD on medication | ||||||||||||||
Paired mean difference | Baseline mean ± SD (n) | Follow-up mean ± SD (n) | T test | Wilcoxon | McNemar | FDR | Paired mean difference | Baseline mean ± SD (n) | Follow-up mean ± SD (n) | T test | Wilcoxon | McNemar | FDR | Baseline (%) | Follow-up (%) | |
tdc-gene abundance | ||||||||||||||||
tdc-gene abundance (outliers removed) | 2.2E−06 | 1.5E−6 ± 1.3E−6 (55) | 3.7E−6 ± 2.6E−6 (55) | 9.7E−07 | n.a. | 8.61E−07 | 2.2E−6 ± 2.2E−6 (54) | 3.1E−6 ± 2.7E−6 (54) | 0.167 | n.a. | ||||||
Gastrointestinal symptoms | ||||||||||||||||
Wexner total score | 0.72 | 5.66 ± 4.01 (67) | 6.37 ± 4.63 (67) | 0.033 | 0.059 | −0.54 | 2.92 ± 2.61 (65) | 2.38 ± 2.58 (65) | 0.010 | 0.030 | ||||||
Rome III (constipation and defecation) | −0.01 | 7.37 ± 5.96 (67) | 7.36 ± 5.17 (67) | 0.685 | 0.685 | −0.22 | 2.97 ± 3.60 (65) | 2.75 ± 3.60 (65) | 0.651 | 0.977 | ||||||
Anti-PD medication exposure | ||||||||||||||||
LEDD (mg) | 116.40 | 444.2 ± 315.6 (66) | 560.6 ± 294.0 (66) | 1.8E−06 | 3E−05 | |||||||||||
Levodopa | ||||||||||||||||
Levodopa IR (mg) | 54.10 | 99.63 ± 159.46 (67) | 153.73 ± 204.92 (67) | 0.028 | 0.221 | 35.8 | 41.8 | |||||||||
Duodopa (mg) | 19.33 | 0.00 ± 0.00 (66) | 19.33 ± 157.06 (66) | 0.317 | 0.708 | 0.0 | 1.5 | |||||||||
Levodopa CR (mg) | −8.96 | 47.76 ± 157.98 (67) | 38.81 ± 115.41 (67) | 1.000 | 1.000 | 11.9 | 14.9 | |||||||||
Levodopa (with entacapone) (mg) | 19.03 | 88.06 ± 220.17 (67) | 107.09 ± 226.33 (67) | 0.513 | 0.872 | 14.9 | 22.4 | |||||||||
COMT inhibitors | ||||||||||||||||
Entacapone (mg) | 49.25 | 146.27 ± 357.74 (67) | 195.52 ± 385.51 (67) | 0.319 | 0.708 | 14.9 | 22.4 | |||||||||
MAO inhibitors | 0.0 | 0.0 | ||||||||||||||
Selegeline (mg) | −0.51 | 4.10 ± 4.84 (67) | 3.59 ± 4.74 (67) | 0.348 | 0.708 | 43.3 | 38.8 | |||||||||
Rasagiline (mg) | 0.06 | 0.25 ± 0.44 (67) | 0.31 ± 0.47 (67) | 0.102 | 0.434 | 25.4 | 31.3 | |||||||||
Dopamine agonists | ||||||||||||||||
Rotigotine (mg) | 0.42 | 0.00 ± 0.00 (67) | 0.42 ± 1.62 (67) | 0.039 | 0.221 | 0.0 | 7.5 | |||||||||
Pramipexole (mg) | −0.06 | 0.62 ± 0.82 (67) | 0.56 ± 0.88 (67) | 0.613 | 0.885 | 43.3 | 38.8 | |||||||||
Ropinirole (mg) | 0.04 | 3.15 ± 5.18 (67) | 3.19 ± 6.02 (67) | 0.951 | 1.000 | 34.3 | 29.9 | |||||||||
Bromocriptine (mg) | n.a. | 0.15 ± 1.22 (67) | 0.15 ± 1.22 (67) | 1.000 | 1.000 | 1.5 | 1.5 | |||||||||
Other medication | ||||||||||||||||
Amantadine (mg) | 1.49 | 6.72 ± 40.73 (67) | 8.21 ± 38.53 (67) | 1.000 | 1.000 | 3.0 | 4.5 | |||||||||
Biperiden (mg) | −0.11 | 0.21 ± 0.94 (67) | 0.10 ± 0.55 (67) | 0.345 | 0.708 | 6.0 | 4.5 | |||||||||
Exelon (mg) | n.a. | 0.00 ± 0.00 (67) | 0.00 ± 0.00 (67) | 1.000 | 1.000 | 0.0 | 0.0 | |||||||||
Use of anacidic (yes/no) | −3% | 6/61 (67) | 4/63(67) | 0.625 | 0.885 | −11% | 7/58 (65) | 0/65 (65) | 0.016 | 0.032 | 9.0 | 6.0 | ||||
Use of anticholinergic (yes/no) | −4% | 6/61 (67) | 3/64(67) | 0.375 | 0.708 | 2% | 0/65 (65) | 1/65 (65) | 1.000 | 1.000 | 9.0 | 4.5 | ||||
